- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space | 1 | Insider Monkey | ||
| 04.03. | TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M | 1 | Seeking Alpha | ||
| 04.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 04.03. | Earnings Breakdown: TScan Therapeutics Q4 | 1 | Benzinga.com | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.03. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | TScan schließt Patientenrekrutierung ab und erhält FDA-Zulassung für neue Krebstherapien | 2 | Investing.com Deutsch | ||
| 26.02. | TScan completes enrollment in trial cohort, receives FDA clearance | 1 | Investing.com | ||
| 26.02. | TScan Therapeutics, Inc.: TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 | 120 | GlobeNewswire (Europe) | Completed enrollment of Cohort C in the Phase 1 ALLOHA trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting... ► Artikel lesen | |
| 12.01. | TScan Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 06.12.25 | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | 184 | GlobeNewswire (Europe) | Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up... ► Artikel lesen | |
| 04.12.25 | TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week | 1 | RTTNews | ||
| 03.12.25 | TScan Therapeutics lädt zu KOL-Event über aktualisierte ALLOHA-Studiendaten | 1 | Investing.com Deutsch | ||
| 03.12.25 | TScan Therapeutics, Inc.: TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials | 6 | Investing.com | ||
| 12.11.25 | Tscan Therapeutics: EPS übertrifft Schätzungen um 0,06 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 12.11.25 | TScan Therapeutics, Inc. Q3 Loss Increases, But Beats Estimates | - | RTTNews | ||
| 12.11.25 | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 74,25 | -0,07 % | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| MEDIGENE | 0,029 | -8,75 % | Medigene: Zurückziehung - 18.11.2025 | ||
| AMGEN | 303,90 | -0,23 % | Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis | Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
VESALIUS-CV Subgroup Findings Reinforce Benefit... ► Artikel lesen | |
| BIOGEN | 163,75 | +0,09 % | Biogen Sayd FDA Grants Approval For High-Dose SPINRAZA Regimen For SMATreatment | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday that the High Dose Regimen of SPINRAZA (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food... ► Artikel lesen | |
| BIOFRONTERA | 2,570 | +0,39 % | Biofrontera: Finanzprognose für das Geschäftsjahr 2026 | Leverkusen (www.anleihencheck.de) - Biofrontera: Finanzprognose für das Geschäftsjahr 2026 - AnleihenewsDer Vorstand der Biofrontera AG (ISIN DE000A4BGGM7/ WKN A4BGGM) gibt heute folgende Finanzprognose... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 653,40 | -0,09 % | Sanofi: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid | Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Approval in moderate-to-severe patients was based on pivotal study results... ► Artikel lesen | |
| EDITAS MEDICINE | 1,949 | -0,10 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| GALAPAGOS NV | 25,420 | 0,00 % | Galapagos NV: Galapagos Announces Nomination of Gino Santini to its Board of Directors | Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine
Mr. Santini will bring extensive corporate governance, business development... ► Artikel lesen | |
| IMMATICS | 8,075 | -0,80 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,130 | +1,80 % | Autolus Therapeutics plc: Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | AUCATZYL (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL UK launch underway following successful... ► Artikel lesen | |
| ONCOPEPTIDES | 0,123 | -7,65 % | Oncopeptides AB: Outcome in Oncopeptides' rights issue | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| AVACTA | 0,730 | -5,81 % | IN BRIEF: Avacta raises GBP10 million in equity for clinical tests | ||
| TANGO THERAPEUTICS | 19,220 | -0,21 % | Tango Therapeutics is the best performing healthcare stock in March | ||
| DERMATA THERAPEUTICS | 1,120 | 0,00 % | Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 | - Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome -- Dermata plans to launch its first DTC product, our Foundational... ► Artikel lesen | |
| KRONOS BIO | 0,880 | 0,00 % | Ignota vacuums up Kronos Bio's drug programmes |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,061 (-6,11 %) liegt der Kurs bei 0,933 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.